Ask about this productRelated genes to: ANXA10 antibody
- Gene:
- ANXA10 NIH gene
- Name:
- annexin A10
- Previous symbol:
- -
- Synonyms:
- ANX14
- Chromosome:
- 4q32.3
- Locus Type:
- gene with protein product
- Date approved:
- 1999-09-17
- Date modifiied:
- 2014-11-18
Related products to: ANXA10 antibody
Related articles to: ANXA10 antibody
- Aberrant expression of mitochondrial quality regulation genes (MQRGs) is intricately linked to mitochondrial dysfunction and the progression of hepatocellular carcinoma (HCC), highlighting the urgent need for reliable prognostic biomarkers. In this study, we aimed to identify differentially expressed MQRGs from 20 candidate genes by analyzing transcriptomic profiles and clinical records from the TCGA (n = 371) and GEO (n = 167) datasets. The identified prognostic MQRGs, along with associated subtype differentially expressed genes (DEGs, n = 156), underwent LASSO and multivariate Cox regression analyses to construct a risk model, which was subsequently validated through time-dependent ROC analysis, Kaplan-Meier curves, and in vitro RT-qPCR. Our findings established a robust 4-MQRG signature comprising ANXA10, BAMBI, AKR1B15, and SPINK1, which revealed that patients classified as high risk had significantly shorter overall survival compared to their low-risk counterparts (p < 0.001). The predictive accuracy of this signature was noteworthy, yielding 1-, 3-, and 5-year AUCs of 0.725, 0.696, and 0.747 in the training cohort (n = 243) and 0.676, 0.627, and 0.592 in the testing cohort (n = 242), respectively. Furthermore, high-risk scores were associated with distinct immunosuppressive tumor microenvironments and varying sensitivity to systemic therapies. The dysregulated expression of the four genes was corroborated by RT-qPCR and analysis of the HPA database. In conclusion, this validated MQRG-based prognostic signature serves as an accurate tool for survival prediction and risk stratification, thus offering valuable biomarker support for personalized therapeutic approaches in HCC. - Source: PubMed
Li BinbinZeng LijunHe ZhilongLuo LunqiLuo YongmeiYi XinyuLi ZhiminZhu HongboLi Yuehua - Circulating proteins act as important hormonal signals of nutrient intake. We aimed to systematically characterise the time-resolved proteomic response to glucose ingestion in humans, and to assess its robustness following prolonged complete caloric restriction. - Source: PubMed
Publication date: 2026/07/17
Uluvar BurulçaWilliamson AliceKolnes Kristoffer JJeppesen Per BendixKolnes Anders JKoprulu MineZoodsma MartijnBeuchel CarlBambal YankiReines MarYasmeen SummairaMaj CarloSchumacher JohannesO'Rahilly Stephenvan Heel David ABartfeld SinaCarrasco-Zanini JuliaJensen JørgenPietzner MaikLangenberg Claudia - Gastric cancer (GC) exhibits marked epidemiological differences between European (EUR) and East Asian (EAS) populations, with significantly higher incidence rates in EAS. Circulating proteins represent promising drug targets; however, most proteomic studies have focused primarily on EUR ancestry, leaving EAS-specific targets largely underexplored. This study aims to identify ancestry-specific plasma protein targets for GC using Mendelian randomization (MR). - Source: PubMed
Publication date: 2026/05/01
Zhi PengCui YanXue GuanghuiQiao LingyuGeng JieChang ZhengyaoXu YinmeiYan JuanjuanWang YingliZhao Chenghui - Esophageal squamous cell carcinoma (ESCC) significantly impacts public health. Variability exists in patients' responses to chemoradiotherapy (CRT), and the role of purinergic signaling (PS) in ESCC, related to tumor migration, remains unclear. - Source: PubMed
Publication date: 2026/03/17
Zhan XiangZhou FenggeYang YuanhuiLei LingliLi MiaoLi JixianFeng AleiQu YanZeng RenyaYang Zhe - Trastuzumab is the first-line therapy for human epidermal growth factor receptor-2 (HER2)-positive gastric cancer (GC). However, intrinsic and acquired resistance due to hyperactivation of intracellular signaling pathway such as MEK/ERK pathways limit its clinical benefits. Plant-derived bioactive compounds have emerged as promising candidates to overcome trastuzumab resistance due to their multi-target effects and favorable safety profiles. - Source: PubMed
Publication date: 2026/03/02
Zhao HuimingYang JumeiYu HongweiLiu HaotianHe QichenLi ZhengyangPan FeifeiWu LeleShi WenguiJiao Zuoyi